What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?

导出 LinkOut

翻译打印收藏纠错

作者： Souhil,Lebdai ^[1] ; Victor,Basset ^[2] ; Julien,Branchereau ^[3] ; Alexandre,de La Taille ^[4] ; Vincent,Flamand ^[5] ; Thierry,Lebret ^[6] ; Thibaut,Murez ^[7] ; Yann,Neuzillet ^[6] ; Guillaume,Ploussard ^[8] ; François,Audenet ^[9]

作者单位： Department of Urology, University Hospital of Angers, 4, rue Larrey, 49933, Angers, France. souhil.lebdai@gmail.com. ^[1] Department of Urology, Assistance publique - Hôpitaux de Paris (AP-HP), Hopital Saint Lois, Paris, France. ^[2] Department of Urology, CHU Nantes Hôtel Dieu, Nantes, France. ^[3] Department of Urology, Assistance publique - Hôpitaux de Paris (AP-HP), Hôpital Henri Mondor, Université Paris XII Val de Marne, Créteil, France. ^[4] Department of Urology, Lille University Hospital, Lille Nord de France University, Lille, France. ^[5] Department of Urology, Foch Hospital, Université Versailles St Quentin en Yvelines, Suresnes, France. ^[6] Department of Urology, Hôpital Lapeyronie, Montpellier, France. ^[7] Department of Urology, Assistance publique - Hôpitaux de Paris (AP-HP), Paris, France. ^[8] Department of Urology, Hôpital Européen Georges Pompidou, Université Paris Descartes, Paris, France. ^[9]

关键词 Abiraterone acetate Cabazitaxel Cross-resistance Docetaxel Enzalutamide Metastatic castration-resistant prostate cancer Therapeutic sequence